0
0
A recent Swedish study has uncovered a promising method to better predict cardiovascular risks in patients newly diagnosed with type 2 diabetes by analyzing specific changes in their DNA. People with type 2 diabetes face up to four times higher chances of heart attacks, strokes, and other major cardiovascular events compared to those without diabetes.
The study involved 752 volunteers with recent type 2 diabetes diagnoses and no prior heart disease. Researchers tracked chemical changes in DNA, called DNA methylation, through regular blood samples taken over approximately seven years. These changes influence which genes are active or inactive in cells, and improper regulation may contribute to cardiovascular disease.
Scientists identified more than 400 DNA methylation sites linked to heart risk and developed a scoring scale using 87 of these sites. The scale effectively identified low-risk patients with 96% accuracy, providing a much-needed tool to distinguish those with potentially higher risk, although its ability to predict high risk was lower (32%), possibly due to limited follow-up time.
This advancement may significantly improve current clinical risk models, which rely on factors like age, gender, blood pressure, smoking status, cholesterol levels, blood sugar, and kidney function but are considered blunt instruments by researchers. Study leader Charlotte Ling of Lund University emphasized that adding DNA methylation analysis greatly enhances future cardiovascular risk prediction in type 2 diabetes patients.
By enabling better identification of individual risk profiles, this test could usher in more personalized treatment plans, optimized healthcare costs, fewer therapy side effects, and reduced patient anxiety.
Disclaimer: This article is based on findings from a Swedish research study published in Cell Reports Medicine and reflects current scientific understanding as released by the researchers. It is intended for informational purposes only and does not substitute professional medical advice. Patients should consult their healthcare providers for personalized risk assessment and treatment choices.
